References
- 1. G. Mancia, E. A. Rosei, E. Ambrosioni, F. Avino, A. Carolei, M. Daccò, G. Di Giacomo, C. Ferri, I. Grazioli, G. Melzi, G. Nappi, L. Pinessi, G. Sandrini, B. Trimarco and G. Zanchin, MIRACLES Study Group. Hypertension and migraine comorbidity: prevalence and risk of cerebrovascular events: evidence from a large, multicenter, cross-sectional survey in Italy (MIRACLES study), J. Hypertens.29 (2011) 309–318; https://doi.org/10.1097/HJH.0b013e328341040410.1097/HJH.0b013e3283410404
- 2. E. P. Widmeier, H. Raff and K. T. Strang, Vander’s Human Physiology: The Mechanisms of Body Function, 13th ed., McGraw-Hill, New York 2014 pp. 408–413.
- 3. S. W. Watts, S. F. Morrison, R. P. Davis and S. M. Barman, Serotonin and blood pressure regulation, Pharmacol. Rev.64 (2012) 359–388; https://doi.org/10.1124/pr.111.00469710.1124/pr.111.004697
- 4. F. Côté, C. Fligny, Y. Fromes, J. Mallet and G. Vodjdani, Recent advances in understanding serotonin regulation of cardiovascular function, Trends Mol. Med.10 (2004) 232–238; https://doi.org/10.1016/j.molmed.2004.03.00710.1016/j.molmed.2004.03.007
- 5. D. W. Dodick and V. Papademetriou, Cardiovascular safety of triptans, Cephalalgia24 (2004) 513–514; https://journals.sagepub.com/doi/10.1111/j.1468-2982.2003.00714.x10.1111/j.1468-2982.2003.00714.x
- 6. V. Tullo, G. Bussone, S. Omboni, P. Barbanti, P. Cortelli, M. Curone, C. Peccarisi, C. Benedetto, D. Pezzola, D. Zava and G. Allais, Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies, Neurol. Sci.34 (2013) 87–91; https://doi.org/10.1007/s10072-013-1367-z10.1007/s10072-013-1367-z
- 7. S. Watts and R. Davis, 5-Hydroxtryptamine receptors in systemic hypertension: an arterial focus, Cardiovasc. Ther.29 (2011) 54–67; https://doi.org/10.1111/j.1755-5922.2010.00173.x10.1111/j.1755-5922.2010.00173.x
- 8. M. Reboredo, H. C. Y. Chang, R. Barbero, C. M. Rodríguez-Ortigosa, F. Pérez-Vizcaíno, A. Morán, M. García, J. M. Banales, N. Carreño, F. Alegre, I. Herrero, J. Quiroga, J. Prieto and B. Sangro, Zolmitriptan: a novel portal hypertensive agent which synergizes with propranolol in lowering portal pressure, PLoS ONE8 (2013) e52683 (9 pages); https://doi.org/10.1371/journal.pone.005268310.1371/journal.pone.0052683
- 9. T. Gori, J. S. Floras and J. D. Parker, Effects of nitroglycerin treatment on baroreflex sensitivity and short-term heart rate variability in humans, J. Am. Coll. Cardiol.40 (2002) 2000–2005; https://doi.org/10.1016/S0735-1097(02)02532-910.1016/S0735-1097(02)02532-9
- 10. A. Negro, L. Lionetto, B. Casolla, N. Lala, M. Simmaco and P. Martelletti, Pharmacokinetic evaluation of frovatriptan, Expert Opin. Drug Metab. Toxicol.7 (2011) 1449–1458; https://doi.org/10.1517/17425255.2011.62226510.1517/17425255.2011.62226521929465
- 11. A. Matthys, G. Haegeman, K. Van Craenenbroeck and P. Vanhoenacker, Role of the 5-HT7 receptor in the central nervous system: from current status to future perspectives, Mol. Neurobiol.43 (2011) 228–253; https://doi.org/10.1007/s12035-011-8175-310.1007/s12035-011-8175-321424680
- 12. D. Guseva, A. Wirth and E. Ponimaskin, Cellular mechanisms of the 5-HT7 receptor-mediated signaling, Front. Behav. Neurosci.8 (2014) Article ID 306 (8 pages); https://doi.org/10.3389/fnbeh.2014.0030610.3389/fnbeh.2014.00306
- 13. M. B. Comer, Pharmacology of the selective 5-HT1B/1D agonist frovatriptan, Headache42 (2002) 47–53; https://doi.org/10.1046/j.1526-4610.42.s2.2.x10.1046/j.1526-4610.42.s2.2.x
- 14. J. Gras, J. Llenas, J. M. Jansat, J. Jáuregui, X. Cabarrocas and J. M. Palacios, Almotriptan, a new anti-migraine agent: a review, CNS Drug Rev.8 (2002) 217–234; https://doi.org/10.1111/j.1527-3458.2002.tb00226.x10.1111/j.1527-3458.2002.tb00226.x
- 15. A. G. Ramage, Central cardiovascular regulation and 5-hydroxytryptamine receptors, Brain Res.Bull.56 (2001) 425–439; https://doi.org/10.1016/S0361-9230(01)00612-810.1016/S0361-9230(01)00612-8
- 16. M. Van den Buuse and N. Wegener, Involvement of serotonin1A receptors in cardiovascular responses to stress: a radio-telemetry study in four rat strains, Eur. J. Pharmacol.507 (2005) 187–198; https://doi.org/10.1016/j.ejphar.2004.11.04810.1016/j.ejphar.2004.11.04815659309
- 17. F. Pagniez, J. P. Valentin, S. Vieu, F. C. Colpaert and G. W. John, Pharmacological analysis of the haemodynamic effects of 5-HT1B/D receptor agonists in the normotensive rat, Br. J. Pharmacol.123 (1998) 205–214; https://doi.org/10.1038/sj.bjp.070159310.1038/sj.bjp.070159315651559489607